Six molecules (etanercept, adalimumab, follitropin alfa, enoxaparin, teriparatide, and insulin aspart) are included in the new structure of incentives for the prescription of the French health system for 2022, together with other measures in force since this month of January.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
